Docetaxel with prednisone or prednisolone for the treatment of ...
Docetaxel with prednisone or prednisolone for the treatment of ...
Docetaxel with prednisone or prednisolone for the treatment of ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Study details and Participant details Intervention details Results Conclusion and<br />
design comments<br />
Auth<strong>or</strong>s’ conclusions:<br />
Chemo<strong>the</strong>rapy <strong>with</strong><br />
mitoxantrone plus<br />
<strong>prednisone</strong> provides<br />
palliation f<strong>or</strong> some patients<br />
<strong>with</strong> symptomatic HRPC<br />
Outcome 1: Overall survival (N = 161)<br />
No significant difference in overall survival; 140 total deaths<br />
(p = 0.27, favouring I group)<br />
Number randomised: 161<br />
Disease characteristics: Sites <strong>of</strong><br />
metastasis:<br />
Auth<strong>or</strong>s: Tannock<br />
et al., 1996 31<br />
Country: Canada<br />
From Mo<strong>or</strong>e et al.: 49<br />
Median survival was 10 months, <strong>with</strong> no difference between<br />
I and C (p = 0.15, favouring I)<br />
Site I: n (%) C: n (%)<br />
Primary source:<br />
MEDLINE<br />
Comments: Supp<strong>or</strong>ted by<br />
Lederle Lab<strong>or</strong>at<strong>or</strong>ies,<br />
Division <strong>of</strong> Cyanamid<br />
Canada Inc.<br />
Univariate regression analysis f<strong>or</strong> time to death (from<br />
Dowling et al. 45 ):<br />
Intervention:<br />
Mitoxantrone +<br />
<strong>prednisone</strong><br />
No. randomised: 80<br />
Route <strong>of</strong> administration:<br />
Mitoxantrone, i.v.;<br />
<strong>prednisone</strong>, <strong>or</strong>ally<br />
Dose: mitoxantrone,<br />
12 mg/m 2 every 3 weeks;<br />
<strong>prednisone</strong>, 5 mg b.d.<br />
Bone 78 (98) 77 (95)<br />
Lymph 18 (22) 15 (19)<br />
Visceral 3 (4) 3 (4)<br />
O<strong>the</strong>r 7 (9) 8 (10)<br />
Variable p HR (95% CI)<br />
PSA concentration: median<br />
(interquartile range)<br />
I, 209 (66–678); C, 158 (42–548)<br />
Aim: To investigate<br />
<strong>the</strong> benefit <strong>of</strong><br />
chemo<strong>the</strong>rapy in<br />
patients <strong>with</strong><br />
symptomatic HRPC<br />
using relevant endpoints<br />
<strong>of</strong> palliation<br />
An independent external<br />
consultant (from National<br />
Cancer Institute <strong>of</strong><br />
Canada) reviewed rec<strong>or</strong>ds<br />
<strong>of</strong> all responding patients<br />
and a randomly selected<br />
series <strong>of</strong> additional patients<br />
Older age 0.26 1.01 (0.99 to 1.03)<br />
Increasing ECOG